Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0069604
Title: Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis
Authors: McCourt, C.M.
McArt, D.G.
Mills, K.
Catherwood, M.A.
Maxwell, P.
Waugh, D.J.
Hamilton, P.
O'Sullivan, J.M.
Salto-Tellez, M. 
Issue Date: 26-Jul-2013
Citation: McCourt, C.M., McArt, D.G., Mills, K., Catherwood, M.A., Maxwell, P., Waugh, D.J., Hamilton, P., O'Sullivan, J.M., Salto-Tellez, M. (2013-07-26). Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis. PLoS ONE 8 (7) : -. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0069604
Abstract: Next Generation Sequencing (NGS) has the potential of becoming an important tool in clinical diagnosis and therapeutic decision-making in oncology owing to its enhanced sensitivity in DNA mutation detection, fast-turnaround of samples in comparison to current gold standard methods and the potential to sequence a large number of cancer-driving genes at the one time. We aim to test the diagnostic accuracy of current NGS technology in the analysis of mutations that represent current standard-of-care, and its reliability to generate concomitant information on other key genes in human oncogenesis. Thirteen clinical samples (8 lung adenocarcinomas, 3 colon carcinomas and 2 malignant melanomas) already genotyped for EGFR, KRAS and BRAF mutations by current standard-of-care methods (Sanger Sequencing and q-PCR), were analysed for detection of mutations in the same three genes using two NGS platforms and an additional 43 genes with one of these platforms. The results were analysed using closed platform-specific proprietary bioinformatics software as well as open third party applications. Our results indicate that the existing format of the NGS technology performed well in detecting the clinically relevant mutations stated above but may not be reliable for a broader unsupervised analysis of the wider genome in its current design. Our study represents a diagnostically lead validation of the major strengths and weaknesses of this technology before consideration for diagnostic use. © 2013 McCourt et al.
Source Title: PLoS ONE
URI: http://scholarbank.nus.edu.sg/handle/10635/110797
ISSN: 19326203
DOI: 10.1371/journal.pone.0069604
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

97
checked on Jan 26, 2023

WEB OF SCIENCETM
Citations

86
checked on Jan 26, 2023

Page view(s)

166
checked on Jan 26, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.